Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Breast cancer recurrence in relation to antidepressant use.

Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM.

Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.

2.

Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Bodai BI, Tuso P.

Perm J. 2015 Spring;19(2):48-79. doi: 10.7812/TPP/14-241. Review.

3.

A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records data.

Lange JM, Hubbard RA, Inoue LY, Minin VN.

Biometrics. 2015 Mar;71(1):90-101. doi: 10.1111/biom.12252. Epub 2014 Oct 15.

4.

Neighborhood influences on recreational physical activity and survival after breast cancer.

Keegan TH, Shariff-Marco S, Sangaramoorthy M, Koo J, Hertz A, Schupp CW, Yang J, John EM, Gomez SL.

Cancer Causes Control. 2014 Oct;25(10):1295-308. doi: 10.1007/s10552-014-0431-1. Epub 2014 Aug 5.

5.

Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS.

Breast Cancer Res Treat. 2014 Apr;144(2):405-16. doi: 10.1007/s10549-014-2870-5. Epub 2014 Feb 21.

6.

Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray S, Bowles EJ, Buist DS.

Breast Cancer Res Treat. 2014 Feb;143(3):541-50. doi: 10.1007/s10549-013-2816-3. Epub 2014 Jan 10.

7.

Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer.

Buist DS, Bosco JL, Silliman RA, Gold HT, Field T, Yood MU, Quinn VP, Prout M, Lash TL; Breast Cancer Outcomes in Older Women (BOW) Investigators.

Breast Cancer Res Treat. 2013 Nov;142(1):153-63. doi: 10.1007/s10549-013-2720-x. Epub 2013 Oct 11.

8.

Frequent antibiotic use and second breast cancer events.

Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1588-99. doi: 10.1158/1055-9965.EPI-13-0454. Epub 2013 Jul 5.

9.

Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study.

Krotneva SP, Reidel KE, Verma A, Mayo N, Tamblyn R, Meguerditchian AN.

Curr Oncol. 2013 Jun;20(3):e212-22. doi: 10.3747/co.20.1293.

10.

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.

Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, Craig Cheetham T, Schottinger JE.

Cancer Med. 2012 Dec;1(3):318-27. doi: 10.1002/cam4.37. Epub 2012 Sep 26.

11.

Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DS.

Cancer Causes Control. 2013 Feb;24(2):305-12. doi: 10.1007/s10552-012-0115-7. Epub 2012 Dec 7.

12.

Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer.

Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, Buist DS.

J Natl Cancer Inst. 2012 Jun 20;104(12):931-40. doi: 10.1093/jnci/djs233. Epub 2012 Apr 30.

13.

Meta-analytic comparison of randomized and nonrandomized studies of breast cancer surgery.

Edwards JP, Kelly EJ, Lin Y, Lenders T, Ghali WA, Graham AJ.

Can J Surg. 2012 Jun;55(3):155-62. doi: 10.1503/cjs.023410. Review.

14.

Does Life Expectancy Affect Treatment of Women Aged 80 and Older with Early Stage Breast Cancers?

Schonberg MA, Marcantonio ER, Ngo L, Silliman RA, McCarthy EP.

J Geriatr Oncol. 2012 Jan 1;3(1):8-16.

15.

Prognostic indices for older adults: a systematic review.

Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK.

JAMA. 2012 Jan 11;307(2):182-92. doi: 10.1001/jama.2011.1966. Review.

16.

The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H.

Breast. 2011 Oct;20 Suppl 3:S1-11. doi: 10.1016/S0960-9776(11)70287-9.

17.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Cronin-Fenton DP, Lash TL.

Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Review.

18.

The influence of travel time on breast cancer characteristics, receipt of primary therapy, and surveillance mammography.

Onega T, Cook A, Kirlin B, Shi X, Alford-Teaster J, Tuzzio L, Buist DS.

Breast Cancer Res Treat. 2011 Aug;129(1):269-75. doi: 10.1007/s10549-011-1549-4. Epub 2011 May 7.

19.

Measurements of Radiation-Induced Skin Changes in Breast-Cancer Radiation Therapy Using Ultrasonic Imaging.

Liu T, Zhou J, Osterman KS, Zhang P, Woodhouse SA, Schiff PB, Kutcher GJ.

Conf Proc IEEE Eng Med Biol Soc. 2008 May 27;2:718-722.

20.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

Items per page

Supplemental Content

Write to the Help Desk